Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023

Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023

ObjectiveOver the past few decades, the development of anti-cancer drugs in China has made outstanding achievements based on the support of national policies. To assess the progress of non-small cell lung cancer (NSCLC) drugs, we conducted a statistical analysis of clinical trials of drugs targeting...

Full description

Bibliographic Details
Main Authors: Wanying Jia, Haiyan Yu, Li Song, Jian Wang, Shuyu Niu, Guojie Zang, Mingjie Liang, Jinwei Liu, Risu Na
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Medicine
Subjects:
non-small cell lung cancer
China
drug clinical trials
registration application
statistical analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1239351/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1239351/full

Similar Items